Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAF156 causal prophylaxis in controlled human malaria challenge
NL-OMON38223Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in malaria and Falciparum malaria (PF) comparing KAF156 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Dec 2013; status: withdrawn.
02
Drugs
ganaplacide
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on NL-OMON38223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38223.